Response Genetics' Q4 Revenues Increase 134 Percent on PGx Test Sales | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics has reported a 134 percent increase in its fourth-quarter revenues, driven by sales of its ResponseDx line of pharmacogenomic tests.

The Los Angeles-based firm brought in total revenues of $3.4 million for the three-month period ended Dec. 31 compared to $1.4 million for the fourth quarter of 2008. The company cited a ramp up in sales of its ResponseDx tests, with revenues growing 81 percent compared to the third quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.